Inovio Biomedical's DNA Vaccine Delivery Technology Moves Ahead in Clinical Trial for Hepatitis C
Inovio initiates 5th DNA vaccine clinical study: hepatitis C
01-Nov-2007 -
Inovio Biomedical Corporation announced that its partner, Tripep AB of Sweden, has begun enrolling patients for its Phase I/II clinical study of a novel DNA vaccine designed to treat chronically infected hepatitis C virus (HCV) patients. The trial will test Tripep's proprietary DNA vaccine, ...
clinical trials
electroporation
hepatitis C
+2